Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2011-10-17

AUTHORS

Reiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, Rumiko Tashima, Yasuo Toyozumi, Nobuyuki Arima

ABSTRACT

BackgroundIn breast cancer, ER/PgR, HER2, and Ki-67 are important biological markers for predicting prognosis and making effective treatment decisions. In addition, changes in markers due to relapse are also clinically experienced; however, the frequency and clinical significance are still not fully understood. Thus, changes in markers and their correlations with prognosis were investigated.Patients and MethodsOut of the patients with relapse from 1997 to March 2011, there were 97 consecutive patients from whom the lesion was resected and evaluated by immunostaining. The biopsy sites were chest wall, lymph node, ipsilateral breast tumor recurrence, lungs, bones, ovaries and brain. The markers sought were ER, PgR, HER2, p53 and Ki-67.ResultsThe hormone receptor positive rate from the primary tumor to recurrence decreased from 63.9% to 57.7% and from 56.7% to 43.3% for ER and PgR, respectively. Changes in the positive/negative evaluation were seen at the rate of 10.3% and 25.8% for ER and PgR, respectively. The Ki-67 index increased significantly from a mean of 29.1% at primary tumor to 36.3% at relapse. When divided into 2 groups (< 50% and ≥50%), changes were seen in 24.7%. On the other hand, the rates of changes in HER2 and p53 positivity were 14.4% and 12.4%. The changes in subtypes were seen in 25%, however, the lowest rate of change was seen in the triple negative cases. Although there was no notable difference in the rate of change between disease-free interval (DFI) and PgR, Ki-67, p53 and HER2, there was a significant difference in the change rates in the ER. A multivariate analysis revealed that the status of distant metastasis and PgR level at relapse, and Ki-67 levels at primary tumor were all significant factors.ConclusionEstrogen receptor and PgR decreased while Ki-67 increased due to relapse; however, the rate of change was high for PgR and Ki-67. Change in the subtypes was seen in 25%. In addition, PgR at relapse and Ki-67 at primary tumor were significant factors for post-relapse prognosis while PgR becoming negative was a poor prognostic factor. These findings are important for making effective treatment decisions. More... »

PAGES

131

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1477-7819-9-131

DOI

http://dx.doi.org/10.1186/1477-7819-9-131

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020283024

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22004841


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoenzyme Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ki-67 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphatic Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Progesterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Suppressor Protein p53", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishimura", 
        "givenName": "Reiki", 
        "id": "sg:person.013173055502.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Osako", 
        "givenName": "Tomofumi", 
        "id": "sg:person.01175256736.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175256736.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okumura", 
        "givenName": "Yasuhiro", 
        "id": "sg:person.01166616331.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166616331.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tashima", 
        "givenName": "Rumiko", 
        "id": "sg:person.0633666302.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633666302.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Toyozumi", 
        "givenName": "Yasuo", 
        "id": "sg:person.01016230102.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016230102.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arima", 
        "givenName": "Nobuyuki", 
        "id": "sg:person.016542450374.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12032-010-9418-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024727343", 
          "https://doi.org/10.1007/s12032-010-9418-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12282-009-0161-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017745614", 
          "https://doi.org/10.1007/s12282-009-0161-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10147-006-0601-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001769831", 
          "https://doi.org/10.1007/s10147-006-0601-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00268-010-0499-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009529309", 
          "https://doi.org/10.1007/s00268-010-0499-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-10-17", 
    "datePublishedReg": "2011-10-17", 
    "description": "BackgroundIn breast cancer, ER/PgR, HER2, and Ki-67 are important biological markers for predicting prognosis and making effective treatment decisions. In addition, changes in markers due to relapse are also clinically experienced; however, the frequency and clinical significance are still not fully understood. Thus, changes in markers and their correlations with prognosis were investigated.Patients and MethodsOut of the patients with relapse from 1997 to March 2011, there were 97 consecutive patients from whom the lesion was resected and evaluated by immunostaining. The biopsy sites were chest wall, lymph node, ipsilateral breast tumor recurrence, lungs, bones, ovaries and brain. The markers sought were ER, PgR, HER2, p53 and Ki-67.ResultsThe hormone receptor positive rate from the primary tumor to recurrence decreased from 63.9% to 57.7% and from 56.7% to 43.3% for ER and PgR, respectively. Changes in the positive/negative evaluation were seen at the rate of 10.3% and 25.8% for ER and PgR, respectively. The Ki-67 index increased significantly from a mean of 29.1% at primary tumor to 36.3% at relapse. When divided into 2 groups (< 50% and \u226550%), changes were seen in 24.7%. On the other hand, the rates of changes in HER2 and p53 positivity were 14.4% and 12.4%. The changes in subtypes were seen in 25%, however, the lowest rate of change was seen in the triple negative cases. Although there was no notable difference in the rate of change between disease-free interval (DFI) and PgR, Ki-67, p53 and HER2, there was a significant difference in the change rates in the ER. A multivariate analysis revealed that the status of distant metastasis and PgR level at relapse, and Ki-67 levels at primary tumor were all significant factors.ConclusionEstrogen receptor and PgR decreased while Ki-67 increased due to relapse; however, the rate of change was high for PgR and Ki-67. Change in the subtypes was seen in 25%. In addition, PgR at relapse and Ki-67 at primary tumor were significant factors for post-relapse prognosis while PgR becoming negative was a poor prognostic factor. These findings are important for making effective treatment decisions.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1477-7819-9-131", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032056", 
        "issn": [
          "1477-7819"
        ], 
        "name": "World Journal of Surgical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "disease-free interval", 
      "primary tumor", 
      "Ki-67", 
      "effective treatment decisions", 
      "breast cancer", 
      "treatment decisions", 
      "ipsilateral breast tumor recurrence", 
      "biological markers", 
      "breast tumor recurrence", 
      "poor prognostic factor", 
      "recurrent breast cancer", 
      "ER/PgR", 
      "Ki-67 levels", 
      "Ki-67 index", 
      "triple-negative cases", 
      "BackgroundIn breast cancer", 
      "important biological marker", 
      "consecutive patients", 
      "lymph nodes", 
      "prognostic factors", 
      "distant metastasis", 
      "tumor recurrence", 
      "p53 positivity", 
      "PgR levels", 
      "clinical significance", 
      "chest wall", 
      "biopsy site", 
      "relapse", 
      "discordance rate", 
      "multivariate analysis", 
      "HER2", 
      "prognosis", 
      "negative cases", 
      "tumors", 
      "patients", 
      "significant factor", 
      "significant differences", 
      "PgR", 
      "recurrence", 
      "lower rates", 
      "cancer", 
      "markers", 
      "p53", 
      "subtypes", 
      "positive rate", 
      "rate of change", 
      "MethodsOut", 
      "ER", 
      "metastasis", 
      "lung", 
      "lesions", 
      "factors", 
      "brain", 
      "positivity", 
      "rate", 
      "receptors", 
      "ovaries", 
      "levels", 
      "notable differences", 
      "differences", 
      "bone", 
      "changes", 
      "status", 
      "group", 
      "findings", 
      "interval", 
      "index", 
      "addition", 
      "significance", 
      "cases", 
      "evaluation", 
      "correlation", 
      "frequency", 
      "negative evaluation", 
      "wall", 
      "decisions", 
      "sites", 
      "hand", 
      "nodes", 
      "analysis", 
      "means", 
      "change rate"
    ], 
    "name": "Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis", 
    "pagination": "131", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020283024"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1477-7819-9-131"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22004841"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1477-7819-9-131", 
      "https://app.dimensions.ai/details/publication/pub.1020283024"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_531.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1477-7819-9-131"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-9-131'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-9-131'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-9-131'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-9-131'


 

This table displays all metadata directly associated to this object as RDF triples.

272 TRIPLES      22 PREDICATES      131 URIs      119 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1477-7819-9-131 schema:about N1083eb74d67947bcb26b10158e7819a4
2 N175211ad4e9f4fb2bbaf0f0658dd8d06
3 N234139abb6bb40c5ba9fed77b13ccf00
4 N26bd08707e82471ab19648fee2fa70f8
5 N4059916020bc46e2a2822a3627e26ecf
6 N57c8b717db7e4fecb95fc4c6d722b2ef
7 N63ab768a2b7d4334b7c645ffb076880c
8 N65fe0fbd294f4309bbe472c067b8476b
9 N69135a90de254577a42174fc46752568
10 N749efae5ddbf42739631f9573d5857fe
11 N7b21b5723478448a84ecdf61a8f39b5b
12 N7f46f9fbe1b44df185b6b0dbe2c71423
13 Naa230b3fbc234586b8361de8ed0b7f83
14 Nab0998fb763341cca16168aa255a1f5a
15 Nae69bb20c15842188c1014d862929a74
16 Ncc2d52ba89ee481fbe5145e339dba6ad
17 Ne139e6bdaefa4d4a989f21a052e5faea
18 Nea9a75edb8a246608f4f048e49363677
19 Nebc63b665dc34b0d98bf1500cfd0bc37
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author N93da97fc282644af9edd02a694e44ecb
23 schema:citation sg:pub.10.1007/s00268-010-0499-z
24 sg:pub.10.1007/s10147-006-0601-6
25 sg:pub.10.1007/s12032-010-9418-2
26 sg:pub.10.1007/s12282-009-0161-5
27 schema:datePublished 2011-10-17
28 schema:datePublishedReg 2011-10-17
29 schema:description BackgroundIn breast cancer, ER/PgR, HER2, and Ki-67 are important biological markers for predicting prognosis and making effective treatment decisions. In addition, changes in markers due to relapse are also clinically experienced; however, the frequency and clinical significance are still not fully understood. Thus, changes in markers and their correlations with prognosis were investigated.Patients and MethodsOut of the patients with relapse from 1997 to March 2011, there were 97 consecutive patients from whom the lesion was resected and evaluated by immunostaining. The biopsy sites were chest wall, lymph node, ipsilateral breast tumor recurrence, lungs, bones, ovaries and brain. The markers sought were ER, PgR, HER2, p53 and Ki-67.ResultsThe hormone receptor positive rate from the primary tumor to recurrence decreased from 63.9% to 57.7% and from 56.7% to 43.3% for ER and PgR, respectively. Changes in the positive/negative evaluation were seen at the rate of 10.3% and 25.8% for ER and PgR, respectively. The Ki-67 index increased significantly from a mean of 29.1% at primary tumor to 36.3% at relapse. When divided into 2 groups (< 50% and ≥50%), changes were seen in 24.7%. On the other hand, the rates of changes in HER2 and p53 positivity were 14.4% and 12.4%. The changes in subtypes were seen in 25%, however, the lowest rate of change was seen in the triple negative cases. Although there was no notable difference in the rate of change between disease-free interval (DFI) and PgR, Ki-67, p53 and HER2, there was a significant difference in the change rates in the ER. A multivariate analysis revealed that the status of distant metastasis and PgR level at relapse, and Ki-67 levels at primary tumor were all significant factors.ConclusionEstrogen receptor and PgR decreased while Ki-67 increased due to relapse; however, the rate of change was high for PgR and Ki-67. Change in the subtypes was seen in 25%. In addition, PgR at relapse and Ki-67 at primary tumor were significant factors for post-relapse prognosis while PgR becoming negative was a poor prognostic factor. These findings are important for making effective treatment decisions.
30 schema:genre article
31 schema:inLanguage en
32 schema:isAccessibleForFree true
33 schema:isPartOf N7bff131074994f1986834df79134dc9f
34 N9b3671441ca84574976b07a397ddf604
35 sg:journal.1032056
36 schema:keywords BackgroundIn breast cancer
37 ER
38 ER/PgR
39 HER2
40 Ki-67
41 Ki-67 index
42 Ki-67 levels
43 MethodsOut
44 PgR
45 PgR levels
46 addition
47 analysis
48 biological markers
49 biopsy site
50 bone
51 brain
52 breast cancer
53 breast tumor recurrence
54 cancer
55 cases
56 change rate
57 changes
58 chest wall
59 clinical significance
60 consecutive patients
61 correlation
62 decisions
63 differences
64 discordance rate
65 disease-free interval
66 distant metastasis
67 effective treatment decisions
68 evaluation
69 factors
70 findings
71 frequency
72 group
73 hand
74 important biological marker
75 index
76 interval
77 ipsilateral breast tumor recurrence
78 lesions
79 levels
80 lower rates
81 lung
82 lymph nodes
83 markers
84 means
85 metastasis
86 multivariate analysis
87 negative cases
88 negative evaluation
89 nodes
90 notable differences
91 ovaries
92 p53
93 p53 positivity
94 patients
95 poor prognostic factor
96 positive rate
97 positivity
98 primary tumor
99 prognosis
100 prognostic factors
101 rate
102 rate of change
103 receptors
104 recurrence
105 recurrent breast cancer
106 relapse
107 significance
108 significant differences
109 significant factor
110 sites
111 status
112 subtypes
113 treatment decisions
114 triple-negative cases
115 tumor recurrence
116 tumors
117 wall
118 schema:name Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
119 schema:pagination 131
120 schema:productId N3e202f120de84afc9479b837f635d358
121 N9750c7e1102f4b0286215059170e7828
122 Nda504aa086e4457292802e6282781cb2
123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020283024
124 https://doi.org/10.1186/1477-7819-9-131
125 schema:sdDatePublished 2022-06-01T22:08
126 schema:sdLicense https://scigraph.springernature.com/explorer/license/
127 schema:sdPublisher N6b9581bf881a488b9420bf019f70461e
128 schema:url https://doi.org/10.1186/1477-7819-9-131
129 sgo:license sg:explorer/license/
130 sgo:sdDataset articles
131 rdf:type schema:ScholarlyArticle
132 N1083eb74d67947bcb26b10158e7819a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Follow-Up Studies
134 rdf:type schema:DefinedTerm
135 N175211ad4e9f4fb2bbaf0f0658dd8d06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Middle Aged
137 rdf:type schema:DefinedTerm
138 N234139abb6bb40c5ba9fed77b13ccf00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Ki-67 Antigen
140 rdf:type schema:DefinedTerm
141 N26bd08707e82471ab19648fee2fa70f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Aged
143 rdf:type schema:DefinedTerm
144 N2cc3296e706a4a5db2e48e467a1ce6a0 rdf:first sg:person.01166616331.89
145 rdf:rest Ncb642af5dba843b0a9866e710c2a3a1e
146 N3e202f120de84afc9479b837f635d358 schema:name doi
147 schema:value 10.1186/1477-7819-9-131
148 rdf:type schema:PropertyValue
149 N4059916020bc46e2a2822a3627e26ecf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Female
151 rdf:type schema:DefinedTerm
152 N48cbb67b21e740b988f7c9b86148af3a rdf:first sg:person.01175256736.52
153 rdf:rest N2cc3296e706a4a5db2e48e467a1ce6a0
154 N48ce8c7944bb4512b9de09e60d4a06a0 rdf:first sg:person.01016230102.90
155 rdf:rest N4b047020cb57469596b12d4c0d2584e9
156 N4b047020cb57469596b12d4c0d2584e9 rdf:first sg:person.016542450374.76
157 rdf:rest rdf:nil
158 N57c8b717db7e4fecb95fc4c6d722b2ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Receptors, Progesterone
160 rdf:type schema:DefinedTerm
161 N63ab768a2b7d4334b7c645ffb076880c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Immunoenzyme Techniques
163 rdf:type schema:DefinedTerm
164 N65fe0fbd294f4309bbe472c067b8476b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Neoplasm Recurrence, Local
166 rdf:type schema:DefinedTerm
167 N69135a90de254577a42174fc46752568 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Tumor Suppressor Protein p53
169 rdf:type schema:DefinedTerm
170 N6b9581bf881a488b9420bf019f70461e schema:name Springer Nature - SN SciGraph project
171 rdf:type schema:Organization
172 N749efae5ddbf42739631f9573d5857fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Receptor, ErbB-2
174 rdf:type schema:DefinedTerm
175 N7b21b5723478448a84ecdf61a8f39b5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Adult
177 rdf:type schema:DefinedTerm
178 N7bff131074994f1986834df79134dc9f schema:volumeNumber 9
179 rdf:type schema:PublicationVolume
180 N7f46f9fbe1b44df185b6b0dbe2c71423 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Receptors, Estrogen
182 rdf:type schema:DefinedTerm
183 N93da97fc282644af9edd02a694e44ecb rdf:first sg:person.013173055502.44
184 rdf:rest N48cbb67b21e740b988f7c9b86148af3a
185 N9750c7e1102f4b0286215059170e7828 schema:name dimensions_id
186 schema:value pub.1020283024
187 rdf:type schema:PropertyValue
188 N9b3671441ca84574976b07a397ddf604 schema:issueNumber 1
189 rdf:type schema:PublicationIssue
190 Naa230b3fbc234586b8361de8ed0b7f83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Neoplasm Staging
192 rdf:type schema:DefinedTerm
193 Nab0998fb763341cca16168aa255a1f5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Biomarkers, Tumor
195 rdf:type schema:DefinedTerm
196 Nae69bb20c15842188c1014d862929a74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Lymphatic Metastasis
198 rdf:type schema:DefinedTerm
199 Ncb642af5dba843b0a9866e710c2a3a1e rdf:first sg:person.0633666302.79
200 rdf:rest N48ce8c7944bb4512b9de09e60d4a06a0
201 Ncc2d52ba89ee481fbe5145e339dba6ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Breast Neoplasms
203 rdf:type schema:DefinedTerm
204 Nda504aa086e4457292802e6282781cb2 schema:name pubmed_id
205 schema:value 22004841
206 rdf:type schema:PropertyValue
207 Ne139e6bdaefa4d4a989f21a052e5faea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Aged, 80 and over
209 rdf:type schema:DefinedTerm
210 Nea9a75edb8a246608f4f048e49363677 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Humans
212 rdf:type schema:DefinedTerm
213 Nebc63b665dc34b0d98bf1500cfd0bc37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Prognosis
215 rdf:type schema:DefinedTerm
216 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
217 schema:name Medical and Health Sciences
218 rdf:type schema:DefinedTerm
219 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
220 schema:name Oncology and Carcinogenesis
221 rdf:type schema:DefinedTerm
222 sg:journal.1032056 schema:issn 1477-7819
223 schema:name World Journal of Surgical Oncology
224 schema:publisher Springer Nature
225 rdf:type schema:Periodical
226 sg:person.01016230102.90 schema:affiliation grid-institutes:grid.415532.4
227 schema:familyName Toyozumi
228 schema:givenName Yasuo
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016230102.90
230 rdf:type schema:Person
231 sg:person.01166616331.89 schema:affiliation grid-institutes:grid.415532.4
232 schema:familyName Okumura
233 schema:givenName Yasuhiro
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166616331.89
235 rdf:type schema:Person
236 sg:person.01175256736.52 schema:affiliation grid-institutes:grid.415532.4
237 schema:familyName Osako
238 schema:givenName Tomofumi
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175256736.52
240 rdf:type schema:Person
241 sg:person.013173055502.44 schema:affiliation grid-institutes:grid.415532.4
242 schema:familyName Nishimura
243 schema:givenName Reiki
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44
245 rdf:type schema:Person
246 sg:person.016542450374.76 schema:affiliation grid-institutes:grid.415532.4
247 schema:familyName Arima
248 schema:givenName Nobuyuki
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76
250 rdf:type schema:Person
251 sg:person.0633666302.79 schema:affiliation grid-institutes:grid.415532.4
252 schema:familyName Tashima
253 schema:givenName Rumiko
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633666302.79
255 rdf:type schema:Person
256 sg:pub.10.1007/s00268-010-0499-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1009529309
257 https://doi.org/10.1007/s00268-010-0499-z
258 rdf:type schema:CreativeWork
259 sg:pub.10.1007/s10147-006-0601-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001769831
260 https://doi.org/10.1007/s10147-006-0601-6
261 rdf:type schema:CreativeWork
262 sg:pub.10.1007/s12032-010-9418-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024727343
263 https://doi.org/10.1007/s12032-010-9418-2
264 rdf:type schema:CreativeWork
265 sg:pub.10.1007/s12282-009-0161-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017745614
266 https://doi.org/10.1007/s12282-009-0161-5
267 rdf:type schema:CreativeWork
268 grid-institutes:grid.415532.4 schema:alternateName Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan
269 Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan
270 schema:name Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan
271 Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto City, Kumamoto, Japan
272 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...